Endoxifen Enteric-Coated
Bipolar 1 Disorder
Jina Pharmaceuticals Inc.Phase 3Active
B
60/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 45/ 100
- Competitive Position
- 89/ 100
Competitive context
33 Active assets in the Bipolar 1 Disorder cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Lurasidone Massachusetts General Hospital | Phase 4 | BBB |
LITHIUM, ELEMENTAL Alzamend Neuro, Inc. | Phase 4 | BBB |
Cipralex Massachusetts General Hospital | Phase 4 | BBB |
Olanzapine Alkermes, Inc. | Phase 4 | BBB |
Valproic Acid Bristol-Myers Squibb | Phase 4 | BBB |
View all 50 →
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →